The Impact of BDNF Polymorphisms on Suicidality in Treatment-Resistant Major Depressive Disorder: A European Multicenter Study

被引:11
|
作者
Schosser, Alexandra [1 ,2 ]
Carlberg, Laura [1 ]
Calati, Raffaella [3 ]
Serretti, Alessandro [4 ]
Massat, Isabel [5 ]
Spindelegger, Christoph [1 ]
Linotte, Sylvie [6 ]
Mendlewicz, Julien [6 ]
Souery, Daniel [7 ,8 ]
Zohar, Joseph [9 ]
Montgomery, Stuart [10 ]
Kasper, Siegfried [1 ]
机构
[1] Med Univ Vienna, Dept Psychiat & Psychotherapy, Wahringer Gurtel 18-20, A-1090 Vienna, Austria
[2] Zentrum Seel Gesundheit, Leopoldau, Austria
[3] Univ Montpellier, FondaMental Fdn, INSERM, U1061, Montpellier, France
[4] Univ Bologna, Dept Biomed & NeuroMotor Sci, Bologna, Italy
[5] Natl Fund Sci Res, Lab Expt Neurol, Brussels, Belgium
[6] Univ Libre Bruxelles, Brussels, Belgium
[7] Univ Libre Bruxelles, Lab Psychol Med, Brussels, Belgium
[8] Psy Pluriel, Ctr Europe Psychol Med, Brussels, Belgium
[9] Chaim Sheba Med Ctr, Tel Hashomer, Israel
[10] Univ London, Sch Med, Imperial Coll, London, England
来源
关键词
BDNF; suicidality; depression; pharmacogenetic; NEUROTROPHIC FACTOR; GENE POLYMORPHISMS; BRAIN; BEHAVIOR; ASSOCIATION; VAL66MET; SIZE;
D O I
10.1093/ijnp/pyx028
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Numerous studies have reported associations between the brain-derived neurotrophic factor (BDNF) gene and psychiatric disorders, including suicidal behavior, although with conflicting results. Methods: A total of 250 major depressive disorder patients were collected in the context of a European multicenter resistant depression study and treated with antidepressants at adequate doses for at least 4 weeks. Suicidality was assessed using the Mini International Neuropsychiatric Interview and Hamilton Rating Scale for Depression, and treatment response using the HAM-D. Genotyping was performed for the functional Val66Met polymorphism (rs6265) and 7 additional tagging single nucleotide polymorphisms within the BDNF gene. Results: Neither BDNF single markers nor haplotypes were found to be associated with suicide risk and lifetime history of suicide attempts. Gender-specific analyses revealed nonsignificant single marker (rs908867) and haplotypic association with suicide risk in males after multiple testing correction. Analyzing treatment response phenotypes, the functional Val66Met polymorphism as well as rs10501087 showed significant genotypic and haplotypic association with suicide risk in remitters (n = 34, 13.6%). Conclusions: Considering the sample size, the present findings need to be replicated in larger samples to confirm or refute a role of BDNF in the investigated suicidal behavior phenotypes.
引用
收藏
页码:782 / 787
页数:6
相关论文
共 50 条
  • [21] Could ketamine be the answer to treating treatment-resistant major depressive disorder?
    Abdullah Mohammed Ramadan
    Islam Ahmed Mansour
    [J]. 上海精神医学, 2020, (05) : 296 - 300
  • [22] Rare Copy Number Variation in Treatment-Resistant Major Depressive Disorder
    O'Dushlaine, Colm
    Ripke, Stephan
    Ruderfer, Douglas M.
    Hamilton, Steven P.
    Fava, Maurizio
    Iosifescu, Dan V.
    Kohane, Isaac S.
    Churchill, Susanne E.
    Castro, Victor M.
    Clements, Caitlin C.
    Blumenthal, Sarah R.
    Murphy, Shawn N.
    Smoller, Jordan W.
    Perlis, Roy H.
    [J]. BIOLOGICAL PSYCHIATRY, 2014, 76 (07) : 536 - 541
  • [23] The study of olanzapine plus fluoxetine in treatment-resistant major depressive disorder without psychotic features
    Shelton, RC
    Tohen, M
    Stahl, S
    Jacobs, T
    Gannon, K
    Tollefson, GD
    [J]. SCHIZOPHRENIA RESEARCH, 2000, 41 (01) : 193 - 193
  • [24] Treatment patterns in patients with treatment-resistant depression in Danish patients with major depressive disorder
    Gronemann, Frederikke Hordam
    Petersen, Janne
    Alulis, Sarah
    Jensen, Kristoffer Jarlov
    Riise, Jesper
    Ankarfeldt, Mikkel Zollner
    Solem, Espen Jimenez
    Bodker, Nikolaj
    Osler, Merete
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2021, 287 : 204 - 213
  • [25] Identification of treatment-resistant major depressive disorder using a machine learning algorithm
    Semeniuta, Daniel
    Marci, Carl
    Bandaria, Jigar
    Zabinski, Joseph W.
    Paulus, Jessica K.
    Orsini, Lucinda
    Boussios, Costas
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 447 - 447
  • [26] Lamotrigine Induces Hair Loss in a Patient With Treatment-Resistant Major Depressive Disorder
    Solmi, Marco
    Tamiello, Gianni Ivo
    Manuli, Giuseppe
    [J]. AMERICAN JOURNAL OF THERAPEUTICS, 2017, 24 (05) : E611 - E612
  • [27] Olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder
    Thase, M. E.
    Corya, S. A.
    Osuntokun, O.
    Sanger, T. M.
    Case, M.
    Watson, S. B.
    Dube, S.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S235 - S236
  • [28] Adjunctive quetiapine for treatment-resistant adolescent major depressive disorder: A case series
    Pathak, S
    Johns, ES
    Kowatch, RA
    [J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2005, 15 (04) : 696 - 702
  • [29] Overcoming treatment-resistant major depressive disorder outside of the doctor's office
    Pereira, Jorge Mota
    Fonte, Daniela
    Teixeira, Ricardo Joao
    Carvalho, Serafim
    [J]. PSYCHIATRY RESEARCH, 2019, 279 : 397 - 398
  • [30] Olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder
    Thase, ME
    Corya, SA
    Osuntokun, O
    Sanger, TM
    Case, M
    Watson, SB
    Dubé, S
    [J]. BIOLOGICAL PSYCHIATRY, 2006, 59 (08) : 210S - 210S